Please ensure Javascript is enabled for purposes of website accessibility

This Caused a 9.7% Pop in PTC Therapeutics' Shares in April

By Todd Campbell - May 7, 2016 at 8:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key backing by regulators in the U.K. rekindled investors' interest in the Duchenne muscular dystrophy drugmaker.

IMAGE SOURCE: PTC THERAPEUTICS.

What: After the U.K.'s healthcare watchdog gave the company's Translarna its blessing last month, shares of PTC Therapeutics (PTCT 4.47%) gained 9.7%, according to data from S&P Global Market Intelligence.

So what: The commercial-stage company markets Translarna for Duchenne muscular dystrophy (DMD) in Europe, and in mid-April, management reported that it had cleared an important hurdle with regulators in England. Specifically, the National Institutes for Health and Care Excellence (NICE) recommended Translarna for ambulatory patients age five years and older with nonsense mutation DMD.

DMD is a tough-to-treat muscle-wasting disease that is caused by a lack of production of dystrophin, a key protein for muscle building. In patients with nonsense mutations, Translarna allows for the production of functional dystrophin. That's important because there are no other approved drugs to treat DMD in Europe, Absent treatment, DMD patients suffer muscle wasting that significantly shortens their average lifespan. Typically, most patients succumb to their disease by their 30s.

Now what: Although Translarna won approval in Europe in late 2014, negotiations must be done with individual member countries before it can be launched there. Therefore, this recommendation by NICE indicates that PTC Therapeutics is making headway in getting Translarna on the market in England.

Nonsense mutations are thought to occur in roughly 13% of DMD patients, and there are only about 50,000 DMD patients in developed countries. In the U.K., about 250 boys are diagnosed with DMD annually and roughly 2,500 people are diagnosed with DMD. Thus, a launch in this market could boost Translarna's addressable patient population by 325 patients. According to NICE, the list price for Translarna is roughly $318,000 per year. PTC Therapeutics will agree to a substantial price cut to open up access to this market, but how much of a discount they offer is anyone's guess. Regardless, this market could still add tens of millions of dollars in annual sales to the company's top line.

Despite this opportunity in England, investors might want to approach this stock cautiously. Earlier this year, the Food and Drug Administration opted against reviewing Translarna for approval in the United States.

Nevertheless, sales of Translarna are growing quickly. The company reported $33.7 million in sales last year, and this week it reported sales of $18.9 million in Q1 2016. That represents a 49% increase versus Q4 and puts the drug on track to deliver on management's guidance for sales of at least $65 million in 2016. 

Given that the company's market cap is only a bit north of $200 million and sales are heading significantly higher, there could be reason for risk-tolerant investors to consider owning this stock. However, anyone who does take the leap will need to remember that operating expenses are still expected to total more than $185 million. That means that there's still a lot of work to be done before this company is profitable.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

PTC Therapeutics, Inc. Stock Quote
PTC Therapeutics, Inc.
PTCT
$41.85 (4.47%) $1.79

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.